JBM Healthcare and Jacobson Pharma Renew Connected Logistics Framework Through 2029

JBM (Healthcare) Ltd. ( (HK:2161) ) has issued an update.

JBM (Healthcare) Limited and Jacobson Pharma Corporation have renewed their framework agreements governing continuing connected transactions, putting in place new arrangements that will run from 1 April 2026 to 31 March 2029. The deals include a 2026 Logistics Services Agreement under which the Jacobson Group will continue to provide logistics services to the JBM Group, with payments settled in Hong Kong dollars within 30 days and an option for either party to terminate with six months’ notice.

Because both companies share a common controlling shareholder, the renewed agreements are classified as continuing connected transactions under Hong Kong listing rules, triggering reporting, announcement and annual review obligations but not requiring shareholder circulars or independent shareholder approval. The renewal ensures operational continuity in logistics support between the two groups while maintaining regulatory compliance, which is important for stakeholders monitoring related-party dealings and governance standards in the listed healthcare and pharma businesses.

The most recent analyst rating on (HK:2161) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on JBM (Healthcare) Ltd. stock, see the HK:2161 Stock Forecast page.

More about JBM (Healthcare) Ltd.

JBM (Healthcare) Limited is a Hong Kong-listed healthcare company that operates alongside Jacobson Pharma Corporation in the pharmaceutical and healthcare sector. The groups engage in logistics and related services to support the distribution and handling of healthcare and pharmaceutical products within their connected corporate structure.

Average Trading Volume: 352,591

Technical Sentiment Signal: Buy

Current Market Cap: HK$2.24B

See more data about 2161 stock on TipRanks’ Stock Analysis page.